Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

This Growth Stock Is Down 20% in the Great Rotation. I Think That's a Mistake.

View original at finance.yahoo.com
This Growth Stock Is Down 20% in the Great Rotation. I Think That's a Mistake. Artificial intelligence (AI) stocks have been leading the market higher for the past few years, but investors hit the emergency brake in 2026, sending many tech stocks suddenly tumbling…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Micron is the best bargain among tech stocks after the rotation

    60% confidence

  • Micron issued robust guidance

    60% confidence

  • All three big DRAM makers are working to sign longer-term contracts for HBM of between three and five years with base volume commitments

    60% confidence

  • Long-term HBM contracts will raise the floor on the DRAM market and make it less cyclical

    60% confidence

  • The current DRAM cycle does not look like an ordinary DRAM cycle due to HBM structural drivers

    60% confidence

  • The move into value and small-cap stocks is not necessarily a bad move with great bargains in the space

    60% confidence

  • Micron's stock looks like a buy after this dip due to the new floor and secular growth trends in AI infrastructure

    60% confidence

  • Investors are clearly questioning Micron's earnings sustainability despite strong current performance

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
This Growth Stock Is Down 20% in the Great Rotation. I Think That's a Mistake. — Source | Via News | ViaNews EU